PTC
CRSP icon

Private Trust Company’s CRISPR Therapeutics CRSP Stock Holding History

Private Trust Company’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164 Sell
3
-2,510
-100% -$132K ﹤0.01% 2659
2026
Q1 		$120K Hold
2,513
– – 0.01% 961
2025
Q4 		$132K Sell
2,513
-100
-4% -$5.99K 0.01% 911
2025
Q3 		$169K Buy
2,613
+2,353
+905% +$135K 0.01% 810
2025
Q2 		$12.6K Buy
260
+160
+160% +$6.19K ﹤0.01% 1733
2025
Q1 		$3.4K Hold
100
– – ﹤0.01% 2160
2024
Q4 		$3.94K Sell
100
-5,151
-98% -$243K ﹤0.01% 2063
2024
Q3 		$247K Buy
5,251
+47
+0.9% +$2.38K 0.02% 622
2024
Q2 		$281K Hold
5,204
– – 0.03% 545
2024
Q1 		$355K Hold
5,204
– – 0.04% 460
2023
Q4 		$326K Buy
5,204
+2,000
+62% +$111K 0.04% 461
2023
Q3 		$145K Hold
3,204
– – 0.02% 669
2023
Q2 		$180K Buy
3,204
+1,104
+53% +$62.6K 0.02% 600
2023
Q1 		$95K Sell
2,100
-2,000
-49% -$97.1K 0.01% 791
2022
Q4 		$167K Buy
4,100
+950
+30% +$50.4K 0.02% 568
2022
Q3 		$206K Buy
3,150
+3,000
+2,000% +$217K 0.03% 471
2022
Q2 		$9K Buy
+150
New +$8.82K ﹤0.01% 1530

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Private Trust Company's CRSP Position: Q2 2026 in Review

Private Trust Company reduced its CRISPR Therapeutics (CRSP) stake by 100% in Q2 2026, selling an estimated $132K and leaving 3 shares worth $164. The position accounts for ﹤0.01% of the portfolio, ranked #2659.

Private Trust Company first reported a position in CRSP in Q2 2022 and has held it in 17 quarters since. The position peaked at $355K in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Private Trust Company held 3 shares of CRISPR Therapeutics worth $164 as of Q2 2026.
  • Private Trust Company sold 2,510 CRISPR Therapeutics shares in Q2 2026, an estimated $132K.
  • CRISPR Therapeutics made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #2659 holding.
  • Private Trust Company first reported a position in CRISPR Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Private Trust Company's CRISPR Therapeutics position peaked at $355K in Q1 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.